← Eichor
Study identifier: NCT06428175 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Hospital-to-Home Transitional Care Interventions (H2H-TCI) Children/Youth With Special Health Care Needs (CYSHCN)

Condition: Health Care · Pediatrics · Transitional Care  ·  Sponsor: Duke University

PhaseNA
Planned participants480
Who can joinAll sexes, N/A to 18 Years
Healthy volunteersNo

About this study

Aim 1: Compare the effectiveness of focused dose vs extended dose hospital-to-home Transitional Care Interventions (H2H-TCI) on health service use and parent-reported confidence for hospitalized CYSHCN. Aim 2: Compare the effectiveness of focused and extended dose H2H-TCI among vulnerable CYSHCN subgroups. Hypothesis: Both H2H-TCI arms will improve primary outcomes more for CYSHCN with higher versus lower clinical complexity; while extended H2H-TCI will better mitigate racial/ethnic outcome disparities than focused H2H-TCI. Aim 3: Evaluate implementation context, processes, and mechanisms via a multi-phase mixed methods study design.

This description comes directly from the study's public registry record.

Talk to the study team

Jennifer Thomas, MPH  ·  (919) 613-5953  ·  jennifer.thomas@duke.edu

Always discuss trial participation with your own doctor first.

Locations (2)

UNC HospitalsChapel Hill, North Carolina, United StatesRecruiting
DUHSDurham, North Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06428175